NCT00550537 2017-06-08Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung CancerVanderbilt-Ingram Cancer CenterPhase 2 Completed116 enrolled 11 charts